论文信息 - Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (aNSCLC). - 字舞流文

Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (aNSCLC).

S. Gettinger | R. Heist | S. Ou | Gregory Riely | A. Wozniak | Dong-Wan Kim | T. Mekhail | S. Gadgeel | P. Schmid | A. Dowlati | G. Oxnard | E. Mitry | P. Foster | J. Spahn | G. Hernandez | I. Sarkar | C. O'Hear